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CASE COMMENT
CHAKRABARTY IN THE ERA OF GENOMICS
Diamond v. Chakrabarty,447 U.S. 303
Brian R. Dorn*
The respondent filed a patent application for the invention of bacteria,'
Pseudomonas,2 stably transformed3 with plasmids 4 that allowed the
bacteria to degrade crude oil. The plasmids containing genes for
hydrocarbon degradative pathways are not found naturally in
Pseudomonas in the environment. This invention was engineered to
provide bioremediation of oil spills. The respondent filed a patent claim
for the bacteria themselves5 , which the patent examiner rejected because
products of nature and living things are not patentable under 35 U.S.C. §
1016 The Patent Office Board of Appeals affirmed the decision of the
Examiner on the grounds that living things are not patentable.7 Then the
Court of Customs and Patent Appeals reversed the decision since the
living nature of microorganisms is irrelevant in regard to patent law. 8 The
United States Supreme Court granted certiorari, affirmed, and HELD, that
a genetically engineered microorganism is not a product of nature, but

* University of Florida, J.D. Candidate, College of Law; Ph.D. Candidate, College of
Medicine; Center for Molecular Microbiology; and Department of Oral Biology, College of
Dentistry.
1. See U.S. Patent No. 4,259,444.
2. Dr. Chakarabarty filed claims for two recombinant Pseudomonasstrains. P. aeruginosa
strain 1c (ATCC 15692) was transformed with plasmids containing genes for octane, salicylate, and
naphthalene degradative pathways to produce P. aeruginosaNRRL B-5472. P. putida NRRL B5473 was created by transforming P. putida strain PpOl (ATCC 17453) with plasmids containing
genes for camphor, salicylate, and naphthalene degradative pathways in addition to RP-1 drug
resistance.
3. Transformation is the transfer of cloned DNA (cDNA) to a competent recipient bacterial

cell.
4. A plasmid is an extrachromosomal genetic element that can stably function and replicate.
In the recombinant'Pseudomonas,the function of the plasmids was to express the degradative
genes.
5. The respondent's claim consisted of the method for producing this bacteria and an
inoculum of a carrier material, to float on the water with the bacteria, in addition to the bacteria
themselves. The patent examiner allowed the first two claims.
6. Diamondv. Chakrabarty,447 U.S. 303, 306 (1980).
7. Id.
8. Id.The Court of Customs and Patent Appeals cited its previous decision in In re Bergy
to support its reversal. 563 F.2d 1031, 1038 (1977).
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rather a product of a person's work and is thus patentable under 35
U.S.C. § 101. 9
To foster ingenuity, Article I, Section 8, Clause 8 of the United States
Constitution allows Congress to provide exclusive rights to an invention
for a limited time.' During the second session of the First Congress, the
legislature quickly used its power to enact the Patent Act of 1790. The
current requirements for patents are codified in Title 35 of the United
States Code. A patent must meet the criteria of proper subject matter" ,
novelty,12 utility 3, nonobviousness 4 , and disclosure.' 5 Once a patent is
granted, the inventor has exclusive rights to6 that invention for twenty years
from the date of filing the patent request. 1
The Court expressly stated a modern view of the public policy
argument for granting patent holders a limited monopoly in the analysis of
Kewanee Oil Co. v. Bicron Corp. 7 The exclusivity granted to patent
holders encourages the risk of the initial costs of the time and money
necessary for research and development.'8 New products, methods, and
ideas theoretically have a positive effect on society as a whole and
improve the quality of life, the economy, etc.' 9 Additionally, new and
innovative ideas stir the creativity of others20° Due to the full disclosure of
the invention during the patent application, society benefits from the
access to the innovations so those with the knowledge and skill can
reproduce the invention after the period of exclusivity expires. 2' The gains
to society outweigh the negative aspects of a limited monopoly. 22
9. ld. at 306-307. The Court granted the petition for certiorari by the Acting Commissioner
of Patents and Trademarks in Bergy, vacated the judgment, and remanded the case to the Court of
Customs and Patent Appeals consistent with the decision of Parker v. Flook. 437 U.S. 584 (1978).
The Court of Customs and Patent Appeals vacated the judgment in Chakrabarty and consolidated
it with Bergy. After another review of Bergy and Chakrabartyconsistent with Flook, the Court of
Customs and Patent Appeals affirmed its earlier decisions. The Court granted certiorari for both
Bergy and Chakrabarty,but Bergy was subsequently dismissed as moot. 444 U.S. 1028 (1980).
Thus, the Court held on Chakrabartyonly.

10. U.S. CoNsT. art. I, §8, cl. 8. "[The Congress shall have Power] To promote the Progress
of Science and useful Arts, by securing for limited Times to Authors and Inventors the exclusive
Right to their respective Writings and Discoveries"
11. 35 U.S.C. § 101 (2000).
12. 35 U.S.C. § 102 (2000).
13. 35 U.S.C. § 101 (2000).
14. 35 U.S.C. § 103 (2000).
15. 35 U.S.C. § 112(2000).
16. 35 U.S.C. § 154(a)(2) (2000).
17. Kewanee Oil Co. v. Bicron Corp, 416 U.S. 470 (1974).

18.
19.
20.
21.
22.

Id. at 480.
Id.
Id. at 481.
Id. at 480-481.
Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127 (1948).
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In Funk Bros. Seed Co. v. Kalo Inoculant Co. 23, the Supreme Court
reviewed a bacterial patent application for the first time. During this
period, farmers inoculated their leguminous crops with monocultures of
Rhizobium species for nitrogen fixation. The two parties isolated strains
that did not have inhibitory effects on other strains, and thus packaged
these strains together so a single mixed culture could be applied to
leguminous plants instead of six separate monocultures. 24 Kalo Inoculant
Co. filed a patent infringement suit against Funk Brothers Seed Co., and
Funk Brothers Seed Co. counterclaimed that the patent was invalid. 25
The Court held that the patent was invalid since the bacterial
characteristics were not created. 2 The bacterial characteristics existed
naturally, but were just unknown to date.2 Hence, the patent applicant did
nothing more than discover an unknown, natural microorganism. 28 Patents
should not be issued for natural phenomena and scientific laws of nature.29
Thirty years later, the Court affirmed the decision of Funk Brothers. In
Parkerv. Flook3° , the Court reviewed a patent application for a "Method
for Updating Alarm Limits." ' 31 The method consisted of 1) a value
measurement of the process variable, 2) an algorithm calculation of a value
32
for the updated alarm limit, and 3) an adjustment to the new alarm limit.
The application represented a novel formula that supplied a better method
to update the alarm limit. 33 Since only the mathematical formula was
novel, the method was not patentable since the formula represents a
mathematical law of nature? 4
The instant Court held that the respondent's genetically engineered
Pseudomonas was patentable under 35 U.S.C. § 101.3 The naturally
occurring microorganism was the basis for the invention, but the plasmid
encoded non-Pseudomonas genes that degraded crude oil made it

23. Id. at 130.
24. Id.
25. Id. at 128, 132.
26. Id. at 131.
27. Id.
28. Id.
29. Id. at 130.
30. Parker v. Flook, 437 U.S. 584 (1978).
31. Within the decision, alarm limits were explained as a predetermined signal of a
measurement of an operating condition (e.g. temperature, pressure) that indicates dangerous
conditions or inefficiency. Since many catalytic conversion processes involve changing variables,
the respondent submitted a patent for determining a method of periodic alarm limit updates.
Essentially, an alarm limit is a number or value.
32. Id. at 585.
33. Id. at 586.
34. Id. at 594.
35. Diamond,supra note 5,at 310.
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patentable subject matter.36 The engineered Pseudomonasdid not occur in
nature. Therefore, the bacteria were not natural phenomena. The Court
found the language of § 101 sufficiently broad to allow inventions of
genetically engineered microorganisms to be patentable." Additionally,
the Committee Reports of the Patent Act of 1952 reported that Congress
intended patentable subject matter "to include anything under the sun that
is made by man. 3a The instant Court also stated that Congress could
amend § 101 if the ruling was against the intent of the legislation.39 Since
the bacteria were man made, the engineered microorganism was
patentable.
The instant Court's ruling allowed a broad reading of patentable subject
matter in the instant case since § 101 did not explicitly bar man made
living organisms. 40 Biotechnology was an emerging field at time of this
decision. Congress could not have envisioned the scope of biotechnology
when the patent laws were enacted. 4 The ambiguity within the law permits
unforeseen developing technologies to be patented. 42
Use of the committee reports also allowed the instant Court to interpret
the legislative intent during the law's formation. 4 The instant Court's
ruling is a continuance of public policy to support biotechnology
developments. The limited exclusivity granted to the inventor provides an
important incentive for further advancements." Much of biotechnology is
a high risk, high reward system. Many products fail or take a long time to
develop due to the complexity of biological systems.45 Additionally, the
product could be copied once injected into the stream of commerce. Thus,
the exclusivity granted to the inventors of genetically engineered

36. Id.

37. Id. at 308.
38. Id. at 309.
39. Id.at 318.
40. Id.

41. Biotechnology is the use of biological pathways, systems, and/or components to make
commercial, research, and/or therapeutic processes and products. Rochelle K. Seide & Janet M.
MacLeod, DraftingClaimsfor Biotechnology Inventions, 543 PLUPAT 377, 381 (1998).
42. Diamond,supra note 5, at 316. The Court did not want to limit the law to what Congress

could envision. Inventions are inherently unforeseeable, and not to protect such inventions would
be at conflict with the basis of patent law. The Congressional discussion of the 1952 Patent Act
was the year before Watson and Crick's landmark article on the description of DNA. James D.
Watson and Francis H.C. Crick, MolecularStructure of Nucleic Acids, 171 NATURE 737 (1953).
Hence, biotechnology was totally unforeseeable to Congress in the creation of the Patent Act of
1952.
43. Id. at 309.
44. See Byron V. Olsen, The Biotechnology BalancingAct: PatentsforGene Fragments,and
Licensing the "UsefulArts," 7 ALB: L.J. Sci. & TECH. 295, 310 (1997).
45. Id.
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microorganisms provides an economic incentive to develop new and
improved technologies.
Due to advancements in molecular genetics,4a large quantity of
research shifted to the genomic level. The entire genomes of many
microorganisms 47 and mammals"s have been sequenced. Genomic
sequences, from bacteria to humans, are readily available on the internet.4 9
With the knowledge of the DNA sequence and the tools to manipulate the
sequences, living organisms are easier to modify, which has led to an
explosion of genetically engineered organisms.
Genetically modified organisms are now used as tools to accomplish
specific goals. Organisms are designed and manipulated to perform
specific functions. Further, the modified organisms do not occur naturally
in the environment. Microorganisms are used as vaccines, 50 gene therapy
vectors,51research tools, 52 and a means to produce industrial-scale volumes
of recombinant proteins.5 3 Under the language in § 101, these
microorganisms are tools just as patentable as man-made chemicals,
machines, or any other manufactured article.
These advancements in biotechnology directly impact society's quality
of life. The impact is most readily visible with new medical therapeutics
and diagnostic tools.5 Biotechnological advancements in agriculture also

46. Diamond, supra note 5, at 318.
47. U.S. CONST. art. 1,
§8, cl. 8.
48. See, e.g., U.S. Patent No. 4,736,866, a transgenic mouse; See, also, U.S. Patent No.
5,557,032, a knockout mouse.
49. Several technical developments of the last twenty years have revolutionalized molecular
biology. For example, polymerase chain reaction (PCR) is a method to exponentially amplify
specific DNA fragments in cycles of dsDNA denaturation, primer annealing, and replication. Now
it is possible to start with miniscule amounts of DNA and amplify the DNA to workable quantities.
More recently, microarray technology uses computer software to assess the mRNA hydbridization
to a microchip and thus approximates the level of gene expression.
50. See, e.g., Frederick R. Blattner, The Complete Genome Sequence of EscherichiaColi K12, 277 SCIENCE 1453, (1997).
51. See International Human Genome Sequencing Consortium, Initial Sequencing and
Analysis of the Human Genome, 409 NATURE 860 (2001); See also J. Craig Venter et al., The
Sequence of the Human Genome, 291 SO.1304 (2001). There are several'current projects to
sequence mammalian genomes including the mouse (http://www.celera.com/MouseGenome).
52. See http://www.ncbi.nlm.nih.gov/Microb-blastunfinishedgenome.html.
53. See, e.g., U.S. Patent No. 5,888,799 issued to Roy Curtiss, i1, who developed a system
whereby a strain of Salmonella enterica serovar Typhimurium presents a desired antigenic
determinant to the immune system. The Salmonella strain is rendered avindent due to deletion
mutations of the adenylate cyclase and cyclic AMP receptor protein genes. The antigenic
determinant of choice (e.g. Streptococcal proteins) is encoded on a plasmid transferred to the
Salmonella. The recombinant vaccine is delivered orally to provide mucosal immunity since
Salmonella localizes to the gut-associated lymphoid tissue. Thus, secretory IgA antibodies are
generated against the antigenic determinant presented by the Salmonella.
54. See, e.g., U.S. Patent No. 5,139,941 issued to Kenneth Berns, Paul Hermanot, Nicholas
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have great promise to increase crop production and to provide greater
quantities of necessary nutrients within the same volume of food.55 Society
benefits from the biotechnology products that enhance health and social
well-being.
The instant Court also implicitly allowed Congress to determine the
patentability of a living organism.5 6 The United States Constitution
specifically grants Congress the duty to legislate the promotion of science
and its discoveries.5 7 Congress has implicitly endorsed the Court's opinion
of the instant case since § 101 has not been amended to expressly exclude
living organisms. Congress can clearly state its intent of the law. In fact,
the United States Patent and Trademark Office (USPTO) subsequently
allowed non-human mammals to be patented under § 101.8 Since the
instant case, Congress continues to allow living organisms to be patentable
subject matter in order to spur biotechnology.
Due to the advancements in genetics and cell biology, scientists have
successfully cloned and patented a variety of mammals.59 Cloned animals
have the potential to be useful in immunological research and in
commercial livestock trade. An international consortium recently
announced that they would attempt to clone a human for infertile

Muzyczka, and Richard Samulski. This group developed a recombinant adeno-associated virus
vector (rAAV) for use as a vector to transduce mammalian cells with exogenous DNA. rAAV
infects humans via the respiratory system, but does not stimulate an immune response. Thus, this
vector has great potential use in gene therapy, e.g cystic fibrosis. For instance, the rAAV could
infect lung tissue and integrate into the host genome. Then the epithelial cells in cystic fibrosis
patients could possibly express a functional cystic fibrosis transmembrane conductance regulator
(CFTR), thereby correcting the defective chloride channel in this genetic disorder.
55. See, e.g., Carmen Alvarez-Dominguez & Philip D. Stahl, IncreasedExpressionof Rab5a
CorrelatesDirectly with AcceleratedMaturationof ListeriaMonocytogenes Phagosomes,274 J.
OF BiOLOGICALCHEMISTRY 11459 (1999). The authors used a Ahly mutant of L monocytogenes,
which remains in a specific intracellular compartment, to determine which isoform of Rab5 signals
early phagosome/endosome maturation.
56. See, e.g., David V. Goeddel et al., Expression in Escherichia coli of Chemically
Synthesized Genes for Human Insulin, 76 PROC. OF THE NAT'L ACAD. OF SCI. USA 106 (1979).
Plasmids containing genes for human insulin were transformed into E. coli. The insulin genes were
expressed in E. coli, and the insulin was extracted and purified. This process decreased the
harvesting of insulin from slaughtered pigs and is able to be performed on an industrial scale.
57. See, e.g., Julian K.-C. Ma, Characterizationof PlantMonoclonalSecretory Antibodies
and Preventive Immunotherapy in Humans, 4 NAT. MED. 601, (1998). This six-month study
demonstrated the preliminary efficacy of a topical application of antibodies to an adhesin of
Streptococcusmutans to prevent tooth decay. The antibodies were produced in transgenic tobacco
plants.
58. See, e.g., Ingo Potyrkus, Golden Rice andBeyond, 125 PLANTPHYSIOLOGY 1157, (2001).
59. See, e.g., Meredith Wadman, Issue of Patents on 'Dolly' Technology Stirs Controversy,
403 Nature 351 (2000); See, also, Elizabeth Pennisi, ClonedMice Provide Companyfor Dolly, 281
Sci. 495 (1998).
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couples.' The USPTO has unequivocally announced that it will not grant
patents to living, human organisms. 6 Although a cloned, living human
organism may be man-made and meet the test of pantentable subject
matter similar to non-human organisms under § 101, a denial of a patent
would almost certainly be upheld by the Court since Congressional
62
committees have been outspoken in their disproval of human cloning.
In the era of genomic research, manipulation and modification of
genomes have produced many organisms that are not found naturally in
the environment. These organisms are patentable subject matter according
to the holding in the instant case. Genetically engineered, living
organisms are not explicitly barred by § 101, thus the ambiguity in patent
law allows new and developing technologies, such as biotechnology in this
case, to be patented. The patents aid emerging technologies to develop.
This fostering of ingenuity is a furtherance of an implicit Congressional
public policy to aid society's advancement and quality of life. By its
inaction, Congress has approved the instant holding and its public policy
ramifications.

60. Sarah Delaney, Scientists Prepare to Clone a Human, WASH. PosT, March 10, 2001, at
A16.
61. Seide & MacLeod, supra note 41, at 384.
62. Rick Weiss, Scientists Testify on Human Cloning Plans, WASH. POST, March 29,2001,
at A10.

